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Scisplatinum doses as high as 225 mg/m2. Doses higher than
100 mg/m2 could be tested also in thymoma patients.
The results of our study highlight a few interesting points:
(1) Patients may survive for prolonged periods despite dis-
ease relapse. (2) Freedom from relapse does not ensure lon-
gevity owing to late deaths from nonthymomatous causes.
(3) Myasthenia in patients with stage IVa disease tends to
persist. (4) There is a moderate rate of contralateral pleural
relapse. (5) More than 10% of the patients are expected to
have a second primary neoplasm. Pleuropneumonectomy,
or extrapleural pneumonectomy in myasthenic patients
and after neoadjuvant chemotherapy, may be associated
with considerable mortality. Considering the entire spec-
trum of these facts along with life quality, we believe that
the approach proposed by us, that is, lung-preserving resec-
tion plus HPCP, may emerge as the preferred treatment for
thymoma patients with pleural spread.
Our study has some of the usual weaknesses of a single-
center nonrandomized study: selection bias and confound-
ing variables. The fact that the response rate to preoperative
chemotherapy in thymoma patients was 88% points to a se-
lection bias from referral centers. The contribution of vari-
ous preoperative and postoperative modalities to survival
could not be analyzed owing to a great variation in means
and timing. A large prospective multicenter trial may over-
come these shortcomings.References
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Dr Joshua R. Sonett (New York, NY). Dr Yellin, thank you for
the delivery of your manuscript and your slides over a month be-
fore the presentation.
I have nothing to disclose except to personally thank you for
helping bring this modality to Columbia over 7 years ago. I am
glad to say that the patient you introduced this therapy to at Colum-
bia is doing quite well.
Your group has to be complimented as one that thought outside
the box about locoregional treatment before it was fashionable and
is assessing it quite soberly and objectively even as you advocate it
as a possible standard.
I have some general points of discussion and 3 questions. Your
best results, as one might expect, were in R0 resections, as with
virtually all thymic resection series. Many would thus argue that
these patients do not need this therapy. Can you tackle this ques-
tion and also help sort out how to definitively prove this is a signif-
icant therapeutic advance, especially given the overall slow
progression of many of these patients and the ability to give sub-
sequent systemic chemotherapy?
Induction chemotherapy for locally advanced thymoma appears
to be effective in reducing tumor burden and increasing R0 resec-
tions. Would you at present advocate or consider systemic chemo-
therapy before your operative treatment with known stage IV
disease to increase your R0 resection preoperatively?
Finally, at Columbia we have pretty much copied your model
for advanced thymoma. However, in pleural mesothelioma we
have developed a model of repeated intrapleural dosing. If chemo-
therapy given once intraoperatively is of probable but not proven
value, why stop at a single dose? All conventional cancer chemo-
therapy is given repeatedly. Repetitive chemotherapy kills a greaterardiovascular Surgery c Volume 145, Number 1 87
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Sfraction of cells as well as cells that have emerged from a chemo-
refractory state. We have thus far shown in patients with pleural
mesothelioma that such chemotherapy can be given over
a 2-month period via indwelling intrapleural catheters, repeated
quite safely and easily. So should we consider this model for stage
IV thymomas, followed by a final resection and heated
chemotherapy?
I thank you and again congratulate you on your pioneering
work.
Dr Yellin. Thank you, Dr Sonett, for your kind remarks and
thoughtful input.
I personally doubt that R0 resection is indeed achievable, al-
though formally that is the case. The philosophy behind the perfu-
sion is to treat invisible small implants. R0 resection yielded the
best results as far as local control was concerned, but it had no im-
pact on overall survival. Unfortunately, the proof that perfusion
has an advantage over any other modality requires a phase 3 study,
which probably will never take place.
Preoperative chemotherapy in our patients was given sporadi-
cally in an unplanned manner. It was not in a neoadjuvant setting.
From our data, it seemed effective but had no impact on the results.
Nevertheless, faced with an invasive mediastinal thymoma or
bulky implants, I would recommend neoadjuvant therapy.
The third question is certainly very interesting. Before address-
ing it, I have to mention a few facts. First, pharmacokinetic studies
have shown that in the perfusion setting, cisplatinum serum con-
centration is almost 0 after 24 hours, which allows for a second
dose. Second, cisplatinum absorption is higher in patients under-
going limited resection compared with those who undergo extrap-
leural pneumonectomy. Third, perfusion is followed very quickly
by severe adhesions. Therefore, I believe that we could indeed re-
peat the dose, but only in a time frame of about a week, not very
much longer. We certainly should consider it. Thank you for the
idea.
Dr David J. Sugarbaker (Boston, Mass). You chose platinum
and doxorubicin as your 2 drugs. In terms of dosing, inasmuch as
there are no data on the appropriate dose of chemotherapeutic
agents placed intrathoracically, do you think that you might be
better served by performing a phase 1 trial to establish the max-
imum tolerated dose? We have done that with mesothelioma, as
presented earlier today. We achieved a dose that was several
times higher than the dose that is given intravenously, 225 versus
100 mg/m2. If you remember Hill’s postulates on the effective-
ness of chemotherapy, effective chemotherapy improves survival
as one is able to increase the concentration and/or dose of
the drug.
I have 2 questions. First, you selected doxorubicin and plati-
num. In the United States, that is not a commonly administered
chemotherapeutic regimen for stage IV thymoma. Second, do
you think that additional studies of the phase 1 type which would
allow for dose escalation and triplets would allow you to maximize
the effect of chemotherapy?
DrYellin.We chose cisplatinum and doxorubicin because those
are 2 of the most common drugs given for thymoma at large and
those are the drugs that worldwide have the largest experience.
We know most about the pharmacokinetics, the side effects, and
so on. We were concerned with the higher doses you have reached
because, with an intact pleura, we should expect higher serum88 The Journal of Thoracic and Cardiovascular Surgelevels, and therefore toxicity could be a bit higher than is seen in
other studies.
Dr Sugarbaker. Are you trying to get all macroscopic disease
resected, in which case I would assume that the pleura was also re-
sected? Is that not the case?
Dr Yellin. Not necessarily. In most cases we did not perform
a total pleurectomy, only a partial pleurectomy. Certainly, the vis-
ceral pleura was intact and part of the mediastinal pleura was intact
and the diaphragmatic pleura stayed intact. We had enough of an
absorption area to increase serum levels.
Dr Sugarbaker. Do you think that all that retained pleura,
which is invariably seeded with tumor cells, may be responsible
somewhat for the survival that you noted? Do you think you might
be better off to do a complete, radical pleurectomy in these cases if
you are not going to do an extrapleural pneumonectomy?
Dr Yellin. Perhaps, but the survival results are at least compa-
rable with those with extrapleural pneumonectomy, and therefore
I am not sure it is indeed required.
Dr Mark J. Krasna (Neptune, NJ). I enjoyed the presentation
and again congratulate you and your group for pushing this for-
ward for many, many years.
As we heard this morning in the mesothelioma talk by Dr Sugar-
baker, it sounds like your group is now using it, and now you are
talking about putting it into a phase 2 study. The message that I
would like to understand is, first, are you ready to say to us that
in prime time we should do this? Are you advocating that off pro-
tocol we should be using intrapleural chemotherapy for the stage
IV diseases, whether you do it as an extrapleural pneumonectomy
or an en bloc macroscopic resection? My second question to both
you and Dr Sugarbaker is, if not, can we get a cooperative group
study? I know many years ago we tried to do a cooperative group
study for mesothelioma to test your phase 2 hypothesis, David. Is it
time to do either a national or international phase 2 or phase 3, ei-
ther in the thymic group or the mesothelioma?
Dr Yellin. I certainly advocate it, but, unfortunately, the Inter-
national Thymic Malignancy Interest Group has decided that an-
other venue is maybe preferred owing to technical difficulties
and institutional review board problems and so on. I believe this
is the best thing to do, but certainly there are many ways to skin
a cat.
Dr Sugarbaker. I would respond to your questions, Mark, with
the following. This study in particular has relatively small num-
bers, and I do not think we can make conclusions as to standard
of care from such a study. I think excellent groundwork has been
laid in single institutional trials for a multi-institutional feasibility
trial to see whether this is exportable. However, with all of the dis-
cussion going on about the performance of macroscopic complete
resection by extrapleural pneumonectomy or pleurectomy by those
who think that those 2 operations are done for the same indication,
which they are not, it certainly indicates that, just like with lung
transplantation that we just heard, esophageal cancer, and lobecto-
mies earlier in this meeting, not everybody who does extrapleural
pneumonectomy, particularly at low frequencies, is going to have
the same perioperative mortality. The recent MARS (Mesotheli-
oma And Radical Surgery) trial had an almost 20% operative mor-
tality, an extremely small number of patients, and it really defies
any conclusions at all about the appropriate procedure. As I men-
tioned this morning, depending on disease distribution, eitherry c January 2013
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long as you are getting 3% or 4% operative mortality for the pneu-
monectomies, should be applied to get a macroscopic complete re-
section. What we need to do is to move on, as you are suggesting
and as the author here is suggesting, to determine what the betterThe Journal of Thoracic and Cextender of surgical margin is in these 2 tumors that recur locally.
What is the best regimen? I think that is where surgeons and oncol-
ogists should be going. We should drop this idea as to which oper-
ation is better, because it is really 2 different operations for 2
different indications and distributions of disease.ardiovascular Surgery c Volume 145, Number 1 89
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